【レポートの概要(一部)】
1. Report Overview
1.1 Overview of Findings: World Market Overview 2015 to 2026
1.2 Why You Should Read This Report
1.3 How This Report Delivers: Chapter Outlines
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About visiongain
2. Introduction to Parkinson’s Disease and its Treatments
2.1 What Causes Parkinson’s?
2.2 Motor Symptoms of Parkinson’s Disease
2.2.1 Tremor: The First Sign of PD
2.2.2 Uncontrolled Muscle Contractions Cause Rigidity
2.2.3 Bradykinesia: The Most Characteristic Feature of Parkinson’s
2.2.4 Postural Instability Manifests as PD Progresses
2.3 Neuropsychiatric Symptoms are Common in PD Patients
2.3.1 Behavioural Deficits are Often the Most Widespread
2.3.2 Cognitive Impairment can Impede Daily Tasks
2.3.3 Autonomic Dysfunction: Another Common Occurrence
2.4 Other Symptoms Associated with Parkinson’s
2.5 Parkinson’s Disease: Diagnosis and Treatment
2.5.1 Diagnosis is Difficult
2.5.2 Treatment Options – Therapeutic Classes
3. Parkinson’s Disease: World Drugs Market, 2016-2026
3.1 Sales of the Overall World PD Drugs Market, 2015-2026
3.2 Parkinson’s Disease: Market Segmentation, 2015
3.3 Overall PD Drug Market: Commercial Drivers and Restraints
3.4 Dopaminergic Agents: Foundation of PD Treatment
3.4.1 Levodopa Therapy
3.4.2 Patent Expiries Affect the Market
3.4.3 New Levodopa Therapies on the Horizon
3.4.4 Dopaminergic Agents: Market Projections to 2026
3.5 Dopamine Receptor Agonists: The Leading Class in 2016
3.5.1 Dopamine Agonists: A Front Line Drug
3.5.2 Advantages over L-Dopa Therapy
3.5.3 Leading Drugs in the Segment
3.5.4 A Healthy R&D Pipeline
3.5.5 Dopamine Receptor Agonists: Market Projections, 2016-2026
3.6 Catechol-O-Methyl Transferase (COMT) Inhibitors: A Popular Choice of Treatment
3.6.1 Entacapone: The Leading Drug in this Segment
3.6.2 Commercial Scope for COMT Inhibitors
3.6.3 COMT Inhibitors: Market Projections, 2016-2026
3.7 Are Monoamine Oxidase–B (MAO-B) Inhibitors Better Than COMT?
3.7.1 MAO-B Inhibitor Therapeutics in the Market
3.7.2 New MAO-B Products in Development
3.7.3 MAO-B Inhibitors: Market Projections, 2016-2026
3.7.4 Other Therapeutic Options: A Growing Opportunity
3.7.5 Generic Erosion in the PD Market
3.7.6 A Broad and Diverse Pharmaceutical Segment
3.7.7 Other Non-medication PD Therapies
3.7.8 The Pipeline Offers Disease Modifying Potential
3.7.9 Other Mechanisms of Action: Market Projections, 2016-2026
4. Leading Companies in the PD Drug Market, 2016
4.1 PD: Novartis sales of Stalevo/Comtan
4.1.1 Market Forecast for Comtan/Stalevo, 2016-2026
4.2 Teva’s Azilect: Past, Present and Future
4.2.1 Market Forecast for Azilect, 2015-2026
4.3 UCB’s Leading Neupro Patch Drug
4.3.1 Market Forecast for Neupro, 2016-2026
4.4 Other Market Players
5. The Leading National Markets, 2016-2026
5.1 Regional Breakdown of the World PD Drug Market, 2016
5.2 The World PD Drug Market: Regional Forecasts to 2026
5.3 The PD Drug Market in the US: The Largest Single National Market
5.3.1 Market Projections for the US, 2015-2026
5.4 The PD Drug Market in the Five Leading European National Markets (EU5), 2016-2026
5.4.1 Market Projections for the EU5, 2016-2026
5.4.2 EU5 Breakdown by Country, 2016
5.4.3 Market Projection for EU5 Countries, Regional Breakdown
5.4.4 Germany: The Largest EU5 Market
5.4.5 France: Strong Healthcare System – What’s Possible There?
5.4.6 UK’s Spending Restrictions Affect the PD Drugs Market
5.4.7 Spain – What Effects Will Austerity Have on PD Drug Sales?
5.4.8 The PD Drug Market in Italy: Rising and Ageing Population
5.5 Japan has the Highest Proportion of Over-65s in the World
5.5.1 Predictions for Japanese PD Drug Market, 2016-2026
5.6 PD Drug Market in Emerging Countries: Brazil, Russia, India and China (BRIC)
5.6.1 Breakdown of BRIC Revenues by Country, 2016
5.6.2 Market Projections for BRIC Nations’ PD Drug Sales, 2016-2026
5.6.3 Brazil’s Rapid Growth of the Pharma Market – What’s the Future?
5.6.4 Russia’s Healthcare Market Gives Generic Sales Opportunities
5.6.5 India: Generic Manufacturers Seek to Dominate the PD Market
5.6.6 China’s Ageing Population Stimulates Sales of PD-Treating Medicines
6. Research and Development for Treating Parkinson’s Disease
6.1 New Mechanisms of Action in the Late-Stage R&D Pipeline
6.2 Growing Potential of Marketed Products: Phase IV Studies
6.3 Phase III Clinical Products Promising Potential in the PD market
6.3.1 IPX203 (Impax Laboratories): The New Generation of Levodopa
6.3.2 Newron’s Safinamide Expected Launch in 2020
6.3.3 Pimavanserin: A First-in-Class Treatment for Parkinson’s Disease Psychosis
6.3.4 Istradefylline: A Promising A(2a) Receptor Antagonist
6.3.5 Termination of Preladenant, APromising A(2a) Receptor Antagonist
6.3.6 Levodopa/Carbidopa Intestinal Gel (LCIG)
6.3.7 Can Opicapone Compete with Existing COMT Inhibitors
6.3.8 Pitolisant: Addressing an Unmet Need
6.3.9 Northera: Oral Precursor of Norepinephrine
6.3.10 Targin by Mundipharm
6.3.11 Nurelinfor Levodopa-Induced Dyskinesia
6.3.12 SYN-115/120: Superior to Istradefylline?
6.4 Phase II PD Pipeline: Overview
6.4.1 Glutamatergic Drugs: Main Target for Pipeline Candidates
6.4.2 Fipamezole: Another Promising A(2a) Receptor Antagonist
6.4.3 CVT-301: A Novel Intrapulmonary Approach
6.4.4 DM-1992: Can Compete with Levodopa Reformulations?
6.4.5 The Accordion Pill Carbidopa/Levodopa by Intec Pharma
6.4.6 Orient Addresses Sialorrhoea
6.4.7 NH004: Formulated with a Muco-Adhesive Property
6.4.8 VR040: A Reformulation of Apomorphine
6.4.9 AVP-923: A Novel Approach for LID-PD
6.4.10 PD Giant Orion, Develop a New Levodopa Drug, ODM-101
6.4.11 News for NeuroDerm’s Reformulations
6.5 Phase I and Pre-clinical PD Pipeline: Overview
6.5.1 Vernalis’ A(2a) Receptor Antagonist Drug in Phase Ib/IIa
6.5.2 Sanofi Collaborates with The Michael J. Fox Foundation
6.5.3 UCL Show Exenatide Potential in Parkinson’s
6.5.4 Titan Pharmaceuticals Develop a Novel Platform
6.6 Neuroprotective Drugs Offer Hope
6.6.1 Phytopharm and Cogane Development
6.6.2 The Potential of Dietary Supplements
6.6.3 GCase Enzymes: Amicus and Biogen Strike A Deal for Parkinson’s
6.6.4 Research Finds Ursodeoxycholic Acid (UDCA) A Potential Cure for Parkinson’s
6.6.5 PD Biomarkers: Potential for Revolutionising Diagnosis and Treatment
6.6.6 Antibody Targeting: The Coming of Age
6.7 Gene Therapy: Promising Research and Technology
6.7.1 ProSavin: Leading Gene Therapy Product
6.7.2 CERE-120 Promises Repair of Damaged Dopaminergic Neurons
6.7.3 AAV-hAADC-2: Another Gene Therapy Contender
6.8 Parthenogenesis (International Stem Cell Corporation): A Promising Outlook for PD Technology
7. Qualitative Analysis of the PD Drug Market, 2016
7.1 SWOT Analysis of the PD Market
7.1.1 Strengths and Weaknesses in the PD Drug Industry in 2016
7.1.2 Opportunities and Threats There from 2016 Onwards
7.2 STEP Analysis of the PD Market
7.2.1 Social Implication of Living with PD
7.2.2 Technological Developments on the Horizon
7.2.3 Economic Pressures: Healthcare Budgeting
7.2.4 Political Issues: Patent Challenges, Data Exclusivity and Regulatory Pathways
8. Research Interviews
8.1 Interview with Dr. Russell Kern (Executive VP, Chief Scientific Officer): International Stem Cell Corporation, California, US
8.1.1 The Overall PD Market
8.1.2 Current Understanding of Stem Cell Therapy
8.1.3 ISCO’s Novel PD Programme
8.1.4 The Potential of Immune-Matching
8.1.5 The Controversy Surrounding Stem Cell Research
8.1.6 The Potential for Parthenogenesis in PD and Other Applications
8.2 Professor Jian Feng PhD, Department of Physiology and Biophysics, University at Buffalo, the State University of New York
8.2.1 A possible Cure
8.2.2 Future Potential: Research
9. Conclusions from the Research and Analysis
9.1 The World PD Market: Predictions to 2026
9.2 Which Therapeutic Class will Dominate the Market in 2026?
9.3 Disease Modification: The Ultimate Goal
9.4 The Future of the Industry and Market for Parkinson’s Medicines
【レポート販売概要】
■ タイトル:パーキンソン病治療薬の世界市場2016-2026■ 英文:Parkinson’s Diseases: World Drug Industry and Market 2016-2026
■ 発行日:2016年5月
■ 調査会社:visiongain
■ 商品コード:VGAIN60623
■ 調査対象地域:グローバル
- 世界の燃焼制御、燃焼制御機器およびシステム市場Combustion process is a complex sequence of chemical reactions taking place between a fuel and an oxidant resulting in the formation of heat. The energy thus produced is used for a number of purposes such as power generation, aircraft and rocket propulsion, and for carrying out various processes in industries. This report primarily deals with all the different types of equipment, controls and syst …
- 不正検出・防止ソリューションの世界市場Fraud detection and prevention solutions and services are the offerings from IT vendors which helps enterprises to take counter measures to fight fraud incidents and occurrences. These solutions detect fraud incidents and prevent enterprises from losing revenue. This report fraud detection and prevention solutions refer to the IT solutions, systems and services which are used to analyze the data a …
- 世界主要国における狂犬病検査市場2015The report presents a detailed analysis of the Rabies diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Rabies definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Commercial …
- 心疾患マーカー検査の世界市場予測:トロポニンI&T、CK-MB、ミオグロビン、BNP、hsCRPThe cardiac marker testing market is expected to reach ~USD 3.50 Billion by 2021 from USD 2.30 Billion in 2016, at a CAGR of 8.8% between 2016 and 2021. Factors such as growing incidences of cardiovascular diseases, the rapidly increasing geriatric population, growing funding from public–private organizations for research on cardiac biomarkers, and ongoing clinical trials for identification of nov …
- 悪性胸水(Malignant Pleural Effusion):世界の治験レビュー2014年下半期版Malignant Pleural Effusion Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Malignant Pleural Effusion Global Clinical Trials Review, H2, 2014" provides data on the Malignant Pleural Effusion clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Pleural Effusion. It includes an overview of the t …
- 油圧シリンダーの世界市場2016-2020:農業、建設業、鉱業、資材運搬機器産業、産業機器産業、航空宇宙・防衛産業About Hydraulic Cylinder The hydraulic cylinder industry will see a steady growth during the forecast period due to a continuous demand from the agriculture, construction equipment, mining equipment, material handling equipment, industrial equipment, aerospace, and defense sectors. Technavio’s analysts forecast the global hydraulic cylinder market to grow at a CAGR of 4.39% during the period 2016- …
- 世界の出張管理サービス市場:手配、購買、計画、予約、アカウント管理、測定、報告などAbout Business Travel Management Business travel management is a specific business function that aligns employee requirements with corporate goals, both on financial and other terms. It helps in realizing cost tracking and control for organizations, facilitates employees to adhere to corporate travel and entertainment (T&E) policies, and generates mass savings through negotiated discounts. It also …
- ガス分析器/ガスセンサ/ガス検知器の世界市場予測(~2021)The gas analyzer market is projected to reach USD 4.06 Billion at CAGR of 5.70% between 2016 and 2021. This high growth is fueled by the increasing demand for GASD due to the implementation of stringent environmental conservation policies, and rising standards on workplace and residential safety. GASD devices are mainly used for measuring safety in any industry to protect their plant and personnel …
- 世界の脳深部刺激装置市場動向(2012-2016)TechNavio’s analysts forecast the Global Deep Brain Stimulator market to grow at a CAGR of 16.99 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rapidly increasing awareness about deep brain stimulation devices in the US. The Global Deep Brain Stimulator market has also been witnessing the emergence of less invasive and non-invasive treatments. H …
- ポリマー被覆布の世界市場予測(~2026):ポリビニル、ポリウレタン、ポリエチレンThe global polymer coated fabrics market is projected to reach USD 26.92 Billion by 2026, at a CAGR of 4.2% from 2016 to 2026.The global polymer coated fabrics market is driven by the increased demand from end-use applications such as, transportation, protective clothing, industrial, furniture & seating, roofing, awnings & canopies, and others including geotextiles, packaging, sports & leisure, ag …
- エアロスタット(軽航空機)の世界市場2016-2020About Aerostat SystemsAn aerostat uses gases lighter than air such as hydrogen, helium, as well as hot air, which helps the aerostat to generate airlift. Aerostats include powered airships and unpowered balloons that are tethered to the ground. These are generally used for intelligence, surveillance, and reconnaissance (ISR) purposes by the military forces and for tourism and civilian observations …
- 防護服の世界市場:材料種類別(アラミド&ブレンド、ポリオレフィン&ブレンド、ポリベンズイミダゾール、綿繊維、積層ポリエステル、その他)、用途別(熱、機械、化学、放射線、その他)、エンドユーザー産業別(石油&ガス、建設&製造、医薬品、法執行&軍事、消防、その他)Global Protective Clothing Market was valued at $8.0 billion in 2018, and is expected to reach $12.9 billion by 2026, supported by a CAGR of 6.2% during the forecast period 2019 to 2026. Innovation in textile industry and launch of new fibers have transformed the familiar functions of conventional textile to the advance textile industry. Protective clothing are manufactured using traditional texti …
- グローバルにおける乳癌治療市場(2014-2018)About Breast Cancer Breast cancer is characterized by the uncontrolled growth of cancerous cells in the breast tissue. It occurs in both males and females; however, male breast cancer is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer and other undifferentiated carcinoma. Ductal carcinoma is the form of breast cancer which starts in the …
- 家族性高コレステロール血症(II型高リポ蛋白血症)(Familial Hypercholesterolemia):治療薬開発パイプライン動向(2015年上半期版)Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H1 2015’, provides an overview of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)’s therapeutic pipeline. This report provides comprehensive information on the therapeutic developme …
- 婦人科系癌の世界市場2019-2023About this market Gynecological cancers are one amongst the most frequently diagnosed cancers in women after breast cancer. The incidence of gynecological cancers such as cervical, uterine, and ovarian cancer is dramatically increasing throughout the world. The increasing incidence can be attributed to risk factors such as obesity, viral infections, smoking, and immune system deficiency. Regional …